Similarly, Brentuximab has shown a remarkable response in CD30-expressing lymphomas (Hodgkin lymphoma, ALCL) and is currently projected as a standard treatment for children with high-risk Hodgkin lymphoma [21]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.